{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:39:56Z","timestamp":1790739596931,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01943","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T08:53:52Z","timestamp":1565772832000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Emilie","family":"Decaup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Gravelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bordenave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Tosolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tourette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Perrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dumontet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Poupot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Savina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Fourni\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bezombes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood."},{"key":"B2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/annonc\/mdw029","article-title":"Breakthrough therapies in B-cell non-Hodgkin lymphoma","volume":"27","author":"Cheah","year":"2016","journal-title":"Ann Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc3930","article-title":"Building better monoclonal antibody-based therapeutics","volume":"15","author":"Weiner","year":"2015","journal-title":"Nat Rev Cancer."},{"key":"B6","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ctrv.2015.07.003","article-title":"Obinutuzumab in hematologic malignancies: lessons learned to date","volume":"41","author":"Illidge","year":"2015","journal-title":"Cancer Treat Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/blood-2013-01-481341","article-title":"Obinutuzumab (GA101) plus CHOP or FC in relapsed\/refractory follicular lymphoma: results of the GAUDI study (BO21000)","volume":"122","author":"Radford","year":"2013","journal-title":"Blood."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00277-016-2878-5","article-title":"Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone","volume":"96","author":"Cheson","year":"2017","journal-title":"Ann Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","article-title":"Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1038\/bcj.2013.32.","article-title":"Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model","volume":"3","author":"Decaup","year":"2013","journal-title":"Blood Cancer J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1158\/1535-7163.MCT-10-0385","article-title":"Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101","volume":"10","author":"Dalle","year":"2011","journal-title":"Mol Cancer Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol Cancer Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3324\/haematol.2010.029520","article-title":"\u03b3\u03b4 T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody","volume":"96","author":"Braza","year":"2011","journal-title":"Haematologica."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1554175","DOI":"10.1080\/2162402X.2018.1554175","article-title":"Boosting \u03b3\u03b4 T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma","volume":"8","author":"Rossi","year":"2018","journal-title":"Oncoimmunology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1189\/jlb.5VMR0415-141R","article-title":"Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions","volume":"99","author":"Battella","year":"2016","journal-title":"J Leukoc Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.leukres.2013.07.038","article-title":"Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma","volume":"37","author":"Shafer","year":"2013","journal-title":"Leuk Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1038\/bcj.2016.67","article-title":"Low natural killer (NK) cell counts in peripheral blood adversely affect clinical outcome of patients with follicular lymphoma","volume":"6","author":"He","year":"2016","journal-title":"Blood Cancer J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/BF03032360","article-title":"Intra-tumoral cytolytic cells: pattern of distribution in B-cell non Hodgkin's lymphoma","volume":"6","author":"Perambakam","year":"2000","journal-title":"Pathol Oncol Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"555","DOI":"10.4161\/onci.19365","article-title":"Innate predisposition to immune escape in follicular lymphoma cells","volume":"1","author":"Gravelle","year":"2012","journal-title":"Oncoimmunology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ajpath.2013.09.018","article-title":"Cell growth in aggregates determines gene expression, proliferation, survival, chemoresistance, and sensitivity to immune effectors in follicular lymphoma","volume":"184","author":"Gravelle","year":"2014","journal-title":"Am J Pathol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4161\/19420862.2015.989020","article-title":"Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies","volume":"7","author":"Duong","year":"2015","journal-title":"mAbs."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.imlet.2014.05.011","article-title":"Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRV\u03b39+ \u03b3\u03b4 T lymphocytes","volume":"161","author":"Decaup","year":"2014","journal-title":"Immunol Lett."},{"key":"B29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene expression omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1182\/blood-2013-07-512392","article-title":"Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma","volume":"123","author":"Brodtkorb","year":"2014","journal-title":"Blood."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1158\/1078-0432.CCR-13-1597","article-title":"EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations","volume":"20","author":"Guo","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e44997","DOI":"10.1371\/journal.pone.0044997","article-title":"An integrated genomic and expression analysis of 7q deletion in splenic marginal zone lymphoma","volume":"7","author":"Watkins","year":"2012","journal-title":"PLoS ONE"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","article-title":"Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma","volume":"121","author":"Green","year":"2013","journal-title":"Blood."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e1188246","DOI":"10.1080\/2162402X.2016.1188246","article-title":"Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas","volume":"5","author":"Tosolini","year":"2016","journal-title":"Oncoimmunology."},{"key":"B36","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.semcancer.2013.08.001","article-title":"The yin and the yang of follicular lymphoma cell niches: role of microenvironment heterogeneity and plasticity","volume":"24","author":"Am\u00e9-Thomas","year":"2014","journal-title":"Semin Cancer Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1182\/blood-2006-05-026203","article-title":"Syk-dependent mTOR activation in follicular lymphoma cells","volume":"108","author":"Leseux","year":"2006","journal-title":"Blood."},{"key":"B39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2007-04-085092","article-title":"PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma","volume":"111","author":"Leseux","year":"2008","journal-title":"Blood."},{"key":"B40","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1182\/blood-2009-08-237537","article-title":"Rituximab inhibits B-cell receptor signaling","volume":"115","author":"Kheirallah","year":"2010","journal-title":"Blood."},{"key":"B41","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1365-2141.2007.06596.x","article-title":"Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas","volume":"137","author":"Behl","year":"2007","journal-title":"Br J Haematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J Clin Invest."},{"key":"B43","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00262-019-02336-6","article-title":"Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy","volume":"68","author":"Sanchez-Correa","year":"2019","journal-title":"Cancer Immunol Immunother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","article-title":"Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL","volume":"131","author":"Vari","year":"2018","journal-title":"Blood."},{"key":"B45","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/MOT.0000000000000243","article-title":"Improving natural killer cell cancer immunotherapy","volume":"20","author":"Berrien-Elliott","year":"2015","journal-title":"Curr Opin Organ Transplant."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T01:55:39Z","timestamp":1569376539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2019.01943"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01943","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,14]]},"article-number":"1943"}}